DEMI-REGROTON
LOE ApproachingNDAORALTABLET
Approved
May 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DEMI-REGROTON is an oral tablet small-molecule NDA approved in 1964 by Sanofi. The specific indication and mechanism of action are not publicly detailed in available data. This legacy product represents a historical pharmaceutical asset with established clinical use.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30) suggests a defensive, cost-focused team managing decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the late-stage lifecycle of this legacy product. Roles on DEMI-REGROTON focus on managing decline, protecting market share against generics, and operational efficiency rather than growth or innovation.
Brand ManagerCommercial Operations Manager
Worked on DEMI-REGROTON at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.